Self-Driving Truck Company Plus Upsizes Recent Fundraising to $420 Million

Globe Newswire

Opioids Market to Reach £31.9 Billion by 2027

Project Details: – StrategyR – A Trademark of Global Industry Analysts, Inc. – Project Edition: 7. – Influencer Pool: 1563. – MarketGlass(TM) Platform – Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.New York, March 31, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Opioids Industry” – https://www.reportlinker.com/p06042706/?utm_source=GNW In addition to being a global intelligence exchange platform, MarketGlass(TM) is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. – Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

Trends & Factors – Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.Mobile Access & App – Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.Complimentary Updates – for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.Bespoke Updates & Team Collaborations – Clients may build a bespoke version of our report with peers on our MarketGlass(TM) platform which enables multidimensional data simulations.

Knowledge Center – clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives. Abstract: – Global Opioids Market to Reach £31.9 Billion by 2027 – Amid the COVID-19 crisis, the global market for Opioids estimated at US£25.4 Billion in the year 2020, is projected to reach a revised size of US£31.9 Billion by 2027, growing at aCAGR of 3.3% over the period 2020-2027. Immediate-Release/Short-Acting Opioid, one of the segments analyzed in the report, is projected to record 2.5% CAGR and reach US£16 Billion by the end of the analysis period.

After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Extended-Release/Long-Acting Opioid segment is readjusted to a revised 4.1% CAGR for the next 7-year period. – The U.S. Market is Estimated at £6.9 Billion, While China is Forecast to Grow at 5.9% CAGR – The Opioids market in the U.S. is estimated at US£6.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US£6.5 Billion by the year 2027 trailing a CAGR of 5.8% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1% and 2.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR. – Select Competitors (Total 31 Featured) – Egalet CorporationJanssen Pharmaceuticals, Inc.Pfizer, Inc.Purdue Pharma LPSanofiSun Pharmaceutical Industries Ltd.West-Ward Pharmaceuticals Corporation Read the full report: https://www.reportlinker.com/p06042706/?utm_source=GNW I. METHODOLOGY II.

EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3.

MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Opioids by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Opioids by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Opioids by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Immediate-Release/Short-Acting Opioid by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Immediate-Release/Short-Acting Opioid by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Immediate-Release/Short-Acting Opioid by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Extended-Release/Long-Acting Opioid by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Extended-Release/Long-Acting Opioid by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Extended-Release/Long-Acting Opioid by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Pain Relief by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Pain Relief by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Pain Relief by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Anesthesia by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Anesthesia by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Anesthesia by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Cough Suppression by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Cough Suppression by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Cough Suppression by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Diarrhea Suppression by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2020 through 2027 and % CAGR Table 20: World Historic Review for Diarrhea Suppression by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 21: World 15-Year Perspective for Diarrhea Suppression by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 22: World Current & Future Analysis for Deaddiction by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2020 through 2027 and % CAGR Table 23: World Historic Review for Deaddiction by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 24: World 15-Year Perspective for Deaddiction by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Table 25: USA Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 26: USA Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 27: USA 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 28: USA Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 29: USA Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 30: USA 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 CANADA Table 31: Canada Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 32: Canada Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 33: Canada 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 34: Canada Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 35: Canada Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 36: Canada 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 JAPAN Table 37: Japan Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 38: Japan Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 39: Japan 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 40: Japan Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 41: Japan Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 42: Japan 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 CHINA Table 43: China Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 44: China Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 45: China 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 46: China Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 47: China Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 48: China 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 EUROPE Table 49: Europe Current & Future Analysis for Opioids by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US£ Million for Years 2020 through 2027 and % CAGR Table 50: Europe Historic Review for Opioids by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 51: Europe 15-Year Perspective for Opioids by Geographic Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 52: Europe Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 53: Europe Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 54: Europe 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 55: Europe Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 56: Europe Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 57: Europe 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 FRANCE Table 58: France Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 59: France Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 60: France 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 61: France Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 62: France Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 63: France 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 GERMANY Table 64: Germany Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 65: Germany Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 66: Germany 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 67: Germany Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 68: Germany Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 69: Germany 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 ITALY Table 70: Italy Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 71: Italy Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 72: Italy 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 73: Italy Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 74: Italy Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 75: Italy 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 76: UK Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 77: UK Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 78: UK 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 79: UK Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 80: UK Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 81: UK 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 SPAIN Table 82: Spain Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 83: Spain Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 84: Spain 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 85: Spain Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 86: Spain Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 87: Spain 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 RUSSIA Table 88: Russia Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 89: Russia Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 90: Russia 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 91: Russia Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 92: Russia Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 93: Russia 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 REST OF EUROPE Table 94: Rest of Europe Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 95: Rest of Europe Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 96: Rest of Europe 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 97: Rest of Europe Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 98: Rest of Europe Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 99: Rest of Europe 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 100: Asia-Pacific Current & Future Analysis for Opioids by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US£ Million for Years 2020 through 2027 and % CAGR Table 101: Asia-Pacific Historic Review for Opioids by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 102: Asia-Pacific 15-Year Perspective for Opioids by Geographic Region – Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 Table 103: Asia-Pacific Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 104: Asia-Pacific Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 105: Asia-Pacific 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 106: Asia-Pacific Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 107: Asia-Pacific Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 108: Asia-Pacific 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 AUSTRALIA Table 109: Australia Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 110: Australia Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 111: Australia 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 112: Australia Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 113: Australia Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 114: Australia 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 INDIA Table 115: India Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 116: India Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 117: India 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 118: India Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 119: India Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 120: India 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 SOUTH KOREA Table 121: South Korea Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 122: South Korea Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 123: South Korea 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 124: South Korea Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 125: South Korea Historic Review for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 126: South Korea 15-Year Perspective for Opioids by End-Use – Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2012, 2020 & 2027 REST OF ASIA-PACIFIC Table 127: Rest of Asia-Pacific Current & Future Analysis for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Table 128: Rest of Asia-Pacific Historic Review for Opioids by Segment – Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid Markets – Independent Analysis of Annual Sales in US£ Million for Years 2012 through 2019 and % CAGR Table 129: Rest of Asia-Pacific 15-Year Perspective for Opioids by Segment – Percentage Breakdown of Value Sales for Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid for the Years 2012, 2020 & 2027 Table 130: Rest of Asia-Pacific Current & Future Analysis for Opioids by End-Use – Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction – Independent Analysis of Annual Sales in US£ Million for the Years 2020 through 2027 and % CAGR Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: https://www.reportlinker.com/p06042706/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution.

Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.__________________________ CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001